D.E. Shaw & Co
HOWL icon

D.E. Shaw & Co’s Werewolf Therapeutics HOWL Stock Holding History

D.E. Shaw & Co’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,776
Closed -$26.3K – 4452
2024
Q4 		$26.3K Buy
+17,776
New +$36.2K ﹤0.01% 4230

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's HOWL Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Werewolf Therapeutics (HOWL) in Q1 2025, closing a stake of 17,776 shares — an estimated $26.3K sold.

D.E. Shaw & Co first reported a position in HOWL in Q4 2024 and held it in 1 quarter. The position peaked at $26.3K in Q4 2024. 70 funds tracked by Wall St. Rank hold HOWL as of Q1 2025.

  • D.E. Shaw & Co reported no remaining Werewolf Therapeutics position as of Q1 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 17,776 Werewolf Therapeutics shares in Q1 2025, an estimated $26.3K.
  • D.E. Shaw & Co first reported a position in Werewolf Therapeutics in Q4 2024 and held it in 1 quarter.
  • D.E. Shaw & Co's Werewolf Therapeutics position peaked at $26.3K in Q4 2024.
  • 70 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.